Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[The PCPT trial].

F C Hamdy1, M Rouprêt

  • 1Academic Urology Unit, Section of Oncology, School of Medicine & Biomedical Sciences, University of Sheffield, Sheffield, UK. F.C.Hamdy@sheffield.ac.uk

Progres En Urologie : Journal De L'Association Francaise D'Urologie Et De La Societe Francaise D'Urologie
|September 26, 2008
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Individual Patient Data Validation of the EAU Definitions of BCG Failure in Patients with Non-muscle-invasive Urothelial Carcinoma of the Bladder: An International Multicenter Retrospective Study.

European urology oncology·2026
Same author

Reply to Letter to the Editor: 'ALBAN (GETUG-AFU 37): a phase 3, randomized, open-label, international trial of intravenous atezolizumab and intravesical Bacillus Calmette-Guérin (BCG) versus BCG alone in BCG-naive high-risk, non-muscle invasive bladder cancer (NMIBC)' by R. Contieri et al.

Annals of oncology : official journal of the European Society for Medical Oncology·2026
Same author

ALBAN (GETUG-AFU 37): a phase III, randomized, open-label international trial of intravenous atezolizumab and intravesical Bacillus Calmette-Guérin (BCG) versus BCG alone in BCG-naive high-risk, non-muscle-invasive bladder cancer (NMIBC).

Annals of oncology : official journal of the European Society for Medical Oncology·2025
Same author

Circulating tumor DNA in muscle-invasive bladder cancer: A systematic review.

Actas urologicas espanolas·2025
Same author

Erdafitinib in BCG-treated high-risk non-muscle-invasive bladder cancer.

Annals of oncology : official journal of the European Society for Medical Oncology·2023
Same author

[Early detection of prostate cancer: Towards a new paradigm?]

Progres en urologie : journal de l'Association francaise d'urologie et de la Societe francaise d'urologie·2023
Same journal

["Connected device for monitoring patients treated by prostatectomy: Implementation and qualitative assessment"].

Progres en urologie : journal de l'Association francaise d'urologie et de la Societe francaise d'urologie·2024
Same journal

[Role of nurses specializing in oncology to support the care journey for patients with penile cancer].

Progres en urologie : journal de l'Association francaise d'urologie et de la Societe francaise d'urologie·2024
Same journal

[Pre- and post-prostatectomy rehabilitation by the certified nurse-urologist pair (REHAB): Feasibility study].

Progres en urologie : journal de l'Association francaise d'urologie et de la Societe francaise d'urologie·2024
Same journal

[Genitourinary complications after pelvic radiotherapy: Diagnosis and management].

Progres en urologie : journal de l'Association francaise d'urologie et de la Societe francaise d'urologie·2024
Same journal

Progres en urologie : journal de l'Association francaise d'urologie et de la Societe francaise d'urologie·2023
Same journal

[Male contraception].

Progres en urologie : journal de l'Association francaise d'urologie et de la Societe francaise d'urologie·2023
See all related articles

The Prostate Cancer Prevention Trial found that finasteride reduced prostate cancer incidence but may increase high-grade cancer detection. Further results are needed to determine its preventative role.

Area of Science:

  • Oncology
  • Urology
  • Clinical Trials

Context:

  • Prostate cancer is a significant health concern for aging men.
  • Chemoprevention strategies are being explored to reduce cancer incidence.
  • The Prostate Cancer Prevention Trial (PCPT) was a large-scale, randomized clinical trial.

Purpose:

  • To evaluate the efficacy of finasteride, a 5-alpha reductase inhibitor, in preventing prostate cancer development.
  • To compare the incidence of prostate cancer in men treated with finasteride versus placebo over a 7-year period.

Summary:

  • The PCPT randomized 18,882 men aged 55+ to receive either 5 mg of finasteride or a placebo daily for 7 years.
  • Prostate cancer incidence was lower in the finasteride group (18.4%) compared to the placebo group (24.4%).

Related Experiment Videos

  • Higher Gleason grade cancers appeared more frequent in the finasteride group, though not statistically significant. Sexual side effects were more common with finasteride.

    • Impact:

    • Finasteride demonstrated a reduction in overall prostate cancer diagnosis.
    • The trial raised concerns about a potential increase in high-grade cancer detection with finasteride.
    • Current data suggests caution in using finasteride for prostate cancer prevention pending further analysis.